Authors: S. Kaur, R. Banerjee
Affilation: Indian Institute of Technology Bombay, India
Pages: 411 - 414
Keywords: nanoparticles, lung cancer, anti-angiogenic agent, combination therapy, aerosol
In the present study, we have conceptualized and formulated a novel delivery vehicle which includes a combination of lipid nanovesicles and polymeric nanoparticles. Main aim of the study is to devise a nanoscale platform technology for combination therapy to be given in aerosolized form for lung cancer treatment. A combination of hydrophobic chemotherapeutic agent and a hydrophillic anti-angiogenic agent is used in this study. Nanoparticles have been shown to have maximum deposition in the alveolar region and maintained the airway patency. A high loading of the drugs is attained in the nanoparticles and release kinetics are such that there is a burst release of the anti-angiogenic agent and a sustained release of paclitaxel. In vitro studies with lung cancer cell lines NCI-H460 and A549 have resulted in significantly low IC50 and high uptake of nanoparticles. The findings of the study suggest that this nanoscale system co-encapsulating a hydrophobic and a hydrophillic agent can be a potential candidate for lung cancer treatment via aerosol route.
Nanotech Conference Proceedings are now published in the TechConnect Briefs